We therefore compared the four TKI in light of their impact on a Ph+ ALL PPI network, taking into account the additional gene copy number alterations that distinguish Ph+ ALL from CML rather than focussing on classical BCR-ABL signaling alone [17]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.